Molecular Testing Lbs

Molecular Awarded a Contract to Participate and Conduct a Clinical Study for Social & Scientific Systems

Published On: October 23, 2018By Categories: Company News/Press/PartnershipsTags: , ,

Share:

Molecular Testing Labs (Molecular) is one of the participants and collaborators with Social & Scientific Systems (SSS) in conducting a large-scale clinical study for the Division of Microbiology and Infectious Diseases (DMID) and National Institutes of Health (NIH). Molecular will participate in developing a protocol and conducting a study to determine the performance of a molecular point-of care-device to detect specific sexually transmitted infections (STIs) known as Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT). In evaluating the performance of the device, the final results will compare to predicate tests previously approved by the FDA.

Molecular is at the forefront of innovation by successfully pioneering effective technology to detect STIs with a dried blood collection kit for the direct-to-consumer at-home testing market. Molecular’s mission is to empower individuals to be able to take charge of their lives by knowing the status of their sexual health. Collaboration with SSS furthers Molecular’s mission to study, innovate and provide avenues to consumers for information about their health and empower them to make proper and timely decisions.

About Molecular Testing Labs:

Molecular Testing Labs is a CLIA and CAP accredited, state-of-the-art, esoteric and reference laboratory. Specializing in high-complexity, molecular testing with an extensive portfolio of services including infectious disease, toxicology, targeted sequencing, single nucleotide polymorphism (SNP) genotyping, Next-Generation Sequencing (NGS), and high-resolution immune profiling. Molecular Testing Labs offers a variety of clinical trial services comprising of assay development, trial site training, investigator support, and customized reporting.

Molecular Testing Labs applies the maximum level of control to obtain the most consistent and highest quality results. Molecular Testing Labs is founded by three guiding principles – Compliance, Innovation, and Partnership.

About Social & Scientific Systems, Inc.:

Social & Scientific Systems, Inc. (SSS) has provided operational and management support to conduct more than 1,800 clinical trials for the National Institutes of Health (NIH) and other clients that have enrolled over 440,000 study participants at more than 650 institutions in over 50 countries, using more than 270 laboratories. SSS is a participant in the Sexually Transmitted Infections Clinical Trials Group (STI CTG). STI CTG is a Division of Microbiology and Infectious Diseases (DMID)/National Institutes of Health (NIH)-sponsored clinical trials group that supports large, randomized clinical trials in the field of prevention, diagnosis, and treatment of sexually transmitted infections.

Media contact for SSS:

Claire Gawryck
cgawryck@s-3.com
301-628-3288

Media contact for Molecular:

Josette Marquand | Marketing & Communications Manager
Press@moleculartestinglabs.com
360-693-8850

About the Author: Staff

MTL
Molecular Testing Labs is headquartered in Vancouver, Washington. Molecular’s leaders are visionary in their approach to precision laboratory diagnostics and are committed to revolutionizing accessibility to testing via proprietary technology systems, advanced logistics, and cutting-edge research and development. They provide laboratory solutions through collaborative partnerships with payors, private healthcare institutions, universities, commercial partners, and public health organizations. Molecular Testing Labs is a CLIA- and CAP-accredited, state-of-the-art reference laboratory that is passionate about bridging the gap and building bonds between the large communities that have access to diagnostics and the smaller underserved communities that deserve that same access. Molecular Testing Labs is pioneering distribution and specimen collection methods that open access to medical testing where geographic, financial, and stigma barriers create gaps in the delivery of healthcare.